Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
41
Journal Issue
26
Date Issued
2023-09-10
Author(s)
Cho, Byoung Chul
Ahn, Myung-Ju
Kang, Jin Hyoung
Soo, Ross A
Reungwetwattana, Thanyanan
Cicin, Irfan
Kim, Dong-Wan
Wu, Yi-Long
Lu, Shun
Lee, Ki Hyeong
Pang, Yong-Kek
Zimina, Anastasia
Fong, Chin Heng
Poddubskaya, Elena
Sezer, Ahmet
How, Soon Hin
Danchaivijitr, Pongwut
Kim, YuKyung
Lim, Yeji
An, Taewon
Lee, Hana
Byun, Hae Mi
Zaric, Bojan
Abstract
Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients with EGFR-mutated (exon 19 deletion [ex19del]/L858R) locally advanced or metastatic non-small-cell lung cancer (NSCLC).
Type
journal article